I read Fuerstein's piece and wonder why he asked Prof. Davis to act as hatchet man. Biotech investors try to avoid scams and shams yet that is what Prof. Davis has concluded about SPHS without any background or basis for his opinion. Granted the company is small and has limited focus but nothing that would suggest a scam. If he has more he should tell us.